Synthesis, Characterization, and In Vitro and In Silico Biological Evaluation of Novel Polyphenols Bearing a Quinazolin-4(3H)-one Ring as Promising Anti-Prostate-Cancer Agents

Abstract

In this study, 12 novel polyphenols containing the quinazolin-4(3H)-one ring were synthesized and characterized using ¹H/¹³C NMR and HRMS analyses, yielding the target compounds in excellent yields (88–96%). Biological evaluation revealed significant cytotoxic activity against PC3 prostate cancer and 3T3 fibroblast cell lines, with compounds 2,2′-(propane-1,3-diyl)bis-3-(2,4-dihydroxybenzylideneamino)quinazolin-4(3H)-one (5) and 2,2′-(propane-1,3-diyl)bis-3-(2,3,4-trihydroxybenzylideneamino)quinazolin-4(3H)-one (6) demonstrating the highest anticancer potential. Compound 6 exhibited the highest selectivity (IC₅₀ = 5.72 µM, SI = 68), outperforming the reference drug, doxorubicin. In silico studies, including molecular docking and dynamics simulations, showed strong binding affinities for mTOR, P110α, and PARP1, particularly for compound 6. Key interactions, such as hydrogen bonds and π-π stacking, contributed to the stability of the 6–mTOR complex. These results highlight compounds 5 and 6 as promising candidates for prostate cancer therapy, with compound 6 showing superior selectivity and interaction profiles, providing the groundwork for further preclinical development.

Key words

hydrazone - quinazolin-4(3H)-one - prostate cancer - cytotoxicity - molecular docking - molecular dynamics

Publikationsverlauf

Eingereicht: 15. Oktober 2024

Angenommen nach Revision: 11. Dezember 2024

Accepted Manuscript online:
11. Dezember 2024

Artikel online veröffentlicht:
17. Januar 2025

• References and Notes

• 1a Şenol H, Çokuludağ K, Aktaş AS, Atasoy S, Dağ A, Topçu G. Org. Commun. 2020; 13: 114
• 1b Tokalı FS, Şenol H, Ateşoğlu Ş, Tokalı P, Akbaş F. J. Mol. Struct. 2025; 1319: 139519
• 1c Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Lancet 2016; 387: 70
• 1d Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Cancer 2004; 101: 2371
• 1e Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. CA: Cancer J. Clin. 2024; 74: 229
• 1f Siegel RL, Miller KD, Fuchs HE, Jemal A. CA: Cancer J. Clin. 2022; 72: 7
• 2 Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong N.-S, Soubeyran I, Sevenet N, Roubaud G. J. Hematol. Oncol. 2021; 14: 51
• 3 Li C, Han Y, Wang Z, Yu Y, Wang C, Ren Z, Guo Y, Zhu T, Li X, Dong S, Ma M. Eur. J. Med. Chem. 2023; 247: 115030
• 4 Crumbaker M, Khoja L, Joshua AM. Cancers 2017; 9: 34
• 5 Şenol H, Ghaffari-Moghaddam M, Bulut Ş, Akbaş F, Köse A, Topçu G. Chem. Biodivers. 2023; 20: e202301089
• 6a Tokalı FS, Şenol H, Ateoglu Ş, Akbaş F. Chem. Biol. Drug Des. 2024; 104: e14599
• 6b Tokali FS, Demir Y, Turkes C, Dincer B, Beydemir S. Drug Dev. Res. 2023; 84: 275
• 6c Tokalı FS, Şenol H, Yetke HI, Hacıosmanoğlu-Aldogan E. Arch. Pharm. (Weinheim) 2023; 356: e2300423
• 6d Tokalı FS, Alım Z, Yırtıcı Ü. ChemistrySelect 2023; 8: e202204191
• 6e Tokali FS. ChemistrySelect 2022; 7: e202204019
• 6f Tokalı FS. Sakarya Univ. J. Sci. 2022; 26: 1117
• 6g El-Azab AS, Abdel-Aziz AA. M, Ghabbour HA, Bua S, Nocentini A, Alkahtani HM, Alsaif NA, Al-Agamy MH. M, Supuran CT. Molecules 2022; 27: 7703
• 6h Mahdy HA, Ibrahim MK, Metwaly AM, Belal A, Mehany AB. M, El-Gamal KM. A, El-Sharkawy A, Elhendawy MA, Radwan MM, Elsohly MA, Eissa IH. Bioorg. Chem. 2020; 94: 103422
• 7 Tokali FS, Taslimi P, Tuzun B, Karakus A, Sadeghian N, Gulcin I. Chem. Biodivers. 2023; 20: e202301134
• 8 Tokalı FS, Taslimi P, Sadeghi M, Şenol H. ChemistrySelect 2023; 8: e202301158
• 9a Farzaliyeva A, Şenol H, Taslimi P, Çakır F, Farzaliyev V, Sadeghian N, Mamedov I, Sujayev A, Maharramov A, Alwasel S, Gulçin İ. J. Mol. Struct. 2025; 1321: 140197
• 9b Zareei S, Mohammadi-Khanaposhtani M, Shahali M, Senol H, Badbedast M, Moazzam A, Mohseni S, Esfahani E, Ekti S, Larijani B, Mahdavi M, Ibrahim E, Ghramh H, Taslimi P. J. Mol. Struct. 2025; 1321
• 9c Kurt BZ, Civelek D. Ö, Çakmak EB, Kolcuoğlu Y, Şenol H, Özkan BN. S, Dag A, Benkli K. J. Med. Chem. 2024; 67: 4463
• 9d Şenol H. ChemistrySelect 2024; 9: e202303927
• 9e Mamedov I, Şenol H, Naghiyev F, Khrustalev V, Sadeghian N, Taslimi P. J. Mol. Liq. 2024; 404: 125006
• 10a Şenol H, Şahin RB, Mercümek B, Kapucu HB, Hacıosmanoğlu E, Dinç HO, Mayda PY. Nat. Prod. Res. 2023; 37: 2500
• 10b Şenol H, Mercümek B, Şahin RB, Kapucu HB, Hacıosmanoğlu E. Results Chem. 2022; 4: 100317
• 10c Şenol H, Ağgül A, Atasoy S, Güzeldemirci NU. J. Mol. Struct. 2023; 1283: 135247
• 10d Osmaniye D, Gorgulu S, Saglik BN, Levent S, Ozkay Y, Kaplancikli ZA. J. Heterocycl. Chem. 2021; 59: 518
• 10e Aydin M, Ozturk A, Duran T, Ozmen UO, Sumlu E, Ayan EB, Korucu EN. J. Med. Mycol. 2023; 33: 101327
• 11a Şenol H, Çakır F. ChemistrySelect 2023; 8: e202302448
• 11b Demirkıran Ö, Erol E, Şenol H, Kesdi İM, Toraman G. ÖA, Okudan E. Ş, Topcu G. Process Biochem. 2024; 136: 90
• 11c Petrova O. gV, Tomilin DN, Şenol H, Belyaeva KV, Nikitina LP, Oparina LA, Sobenina LN, Trofimov BA, Sadeghian N, Taslimi P, Farzaliyev V, Sujayev A, Gulçin İ. J. Mol. Struct. 2024; 1315: 138998
• 11d Şenol H, Ghaffari-Moghaddam M, Toraman G. ÖA, Güller U. J. Mol. Struct. 2024; 1295: 136804
• 11e Şenol H, Ghaffari-Moghaddam M, Bulut Ş, Akbas F, Köse A, Topçu G. Chem. Biodivers. 2023; 20: e202301089
• 11f Kılınç N, Açar M, Tuncay S, Karasakal F. Ö. Lett. Drug Des. Discovery 2022; 19: 996
• 11g Kılınç N. Int. J. Chem. Technol. 2021; 5: 77